BR112022022305A2 - Combinação farmacêutica que compreende tno155 e nazartinibe - Google Patents

Combinação farmacêutica que compreende tno155 e nazartinibe

Info

Publication number
BR112022022305A2
BR112022022305A2 BR112022022305A BR112022022305A BR112022022305A2 BR 112022022305 A2 BR112022022305 A2 BR 112022022305A2 BR 112022022305 A BR112022022305 A BR 112022022305A BR 112022022305 A BR112022022305 A BR 112022022305A BR 112022022305 A2 BR112022022305 A2 BR 112022022305A2
Authority
BR
Brazil
Prior art keywords
tno155
nazartinib
pharmaceutical combination
treatment
pharmaceutical
Prior art date
Application number
BR112022022305A
Other languages
English (en)
Portuguese (pt)
Inventor
Hao Huaixiang
Liu Chen
E Moody Susan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112022022305A2 publication Critical patent/BR112022022305A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112022022305A 2020-05-08 2021-05-06 Combinação farmacêutica que compreende tno155 e nazartinibe BR112022022305A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063021772P 2020-05-08 2020-05-08
US202063117388P 2020-11-23 2020-11-23
PCT/IB2021/053867 WO2021224867A1 (en) 2020-05-08 2021-05-06 Pharmaceutical combination comprising tno155 and nazartinib

Publications (1)

Publication Number Publication Date
BR112022022305A2 true BR112022022305A2 (pt) 2022-12-20

Family

ID=75904981

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022022305A BR112022022305A2 (pt) 2020-05-08 2021-05-06 Combinação farmacêutica que compreende tno155 e nazartinibe

Country Status (12)

Country Link
US (1) US20230172928A1 (cg-RX-API-DMAC7.html)
EP (1) EP4146217A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023524789A (cg-RX-API-DMAC7.html)
KR (1) KR20230008719A (cg-RX-API-DMAC7.html)
CN (1) CN115397421A (cg-RX-API-DMAC7.html)
AU (1) AU2021267213B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022022305A2 (cg-RX-API-DMAC7.html)
CA (1) CA3179994A1 (cg-RX-API-DMAC7.html)
IL (1) IL297043A (cg-RX-API-DMAC7.html)
MX (1) MX2022013867A (cg-RX-API-DMAC7.html)
TW (1) TW202207933A (cg-RX-API-DMAC7.html)
WO (1) WO2021224867A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL304526B2 (en) 2018-09-29 2025-05-01 Novartis Ag Production of compounds and preparations for inhibiting the activity of SHP2
EP3856345A1 (en) 2018-09-29 2021-08-04 Novartis AG Process of manufacture of a compound for inhibiting the activity of shp2
ES3040751T3 (en) 2020-07-08 2025-11-04 Novartis Ag Manufacture of compounds and compositions for inhibiting the activity of shp2
AU2022341107A1 (en) 2021-09-08 2024-02-29 Amgen Inc. Sotorasib and an egfr antibody for treating cancer comprising a kras g12c mutation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CN110730678B (zh) * 2017-01-10 2022-07-15 诺华股份有限公司 包含alk抑制剂和shp2抑制剂的药物组合
EP3856345A1 (en) * 2018-09-29 2021-08-04 Novartis AG Process of manufacture of a compound for inhibiting the activity of shp2

Also Published As

Publication number Publication date
IL297043A (en) 2022-12-01
AU2021267213B2 (en) 2023-11-30
TW202207933A (zh) 2022-03-01
JP2023524789A (ja) 2023-06-13
AU2021267213A1 (en) 2022-11-03
CN115397421A (zh) 2022-11-25
WO2021224867A1 (en) 2021-11-11
US20230172928A1 (en) 2023-06-08
KR20230008719A (ko) 2023-01-16
EP4146217A1 (en) 2023-03-15
CA3179994A1 (en) 2021-11-11
MX2022013867A (es) 2022-11-30

Similar Documents

Publication Publication Date Title
CL2021002099A1 (es) Combinación farmacéutica que comprende tno155 y ribociclib.
MX2021009562A (es) Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1.
EP4249000A3 (en) Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
JOP20220167A1 (ar) مثبطات sarm1
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
BR112022023013A2 (pt) Inibidores de mek para tratamento ou prevenção de infecções por coronavírus e/ou de tempestade de citocinas de covid-19
AR119934A1 (es) Inhibidores de pikfyve para terapia contra el cáncer
BR112022005896A2 (pt) Inibidores da mek para o tratamento de infecções causadas por hantavírus
MX2024000271A (es) Inhibidor de shp2 y uso del mismo.
BR112022011421A2 (pt) Inibidores da proteína mutante kras
EA201992220A1 (ru) Комбинированная терапия для лечения или предупреждения опухолей
BR112021022758A2 (pt) Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos
JOP20230037A1 (ar) مثبطات sarm1
BR112022001341A2 (pt) Inibidores de enzima
MX2024008115A (es) Tratamiento conjunto para tratamiento contra el cancer.
MX2022013867A (es) Combinacion farmaceutica que comprende tno155 y nazartinib.
BR112022001025A2 (pt) Inibidores de calicreína plasmática
BR112022021562A2 (pt) Partículas interferentes terapêuticas para o coronavírus
BR112023001792A2 (pt) Combinações para o tratamento de câncer
MX2022013081A (es) Compuestos para el tratamiento de sars.
CO2022000270A2 (es) Inhibidores de enzimas
WO2022020353A3 (en) Methods and compositions for treatment and prevention of coronavirus infection
MX2023015121A (es) Metodos de uso de inhibidores de aldosterona sintasa.
CO2023012342A2 (es) Inhibidores de enzimas
BR112022023187A2 (pt) Compostos para o tratamento da sars